<DOC>
	<DOCNO>NCT02072200</DOCNO>
	<brief_summary>This study multicenter , Ph IV , single arm , interventional study assess relative reduction morning stiffness Lodotra® Rheumatoid Arthritis patients.Study medication start study visit baseline ( week 0 , visit 1 ) follow-up visit 2 , 6 12 week treatment ( visit 2,3,4 ) .</brief_summary>
	<brief_title>Efficacy Lodotra® ( Prednisone ) Reduction Morning Stiffness Duration ( K-IMPROvE )</brief_title>
	<detailed_description>Test Treatment , Dose , Mode Administration : Starting dose 10mg , depend clinical symptom patient 's response , initial dose quickly reduce low maintenance dose . When change standard regimen ( glucocorticoid administration morning ) Lodotra® administer bedtime ( 10 pm ) , dose ( mg prednisone equivalent ) maintain , subject take stable dose within 30 day . Lodotra® dose exceed 10mg . Lodotra® take bedtime ( 10 pm ) , even meal swallow whole sufficient liquid . If 2 - 3 hour pass since even meal , recommend take Lodotra® light meal snack . Modified-release tablet break , divide chewed . Treatment procedure : At Visit 1 ( week 0 ) , subject qualify entry study medicate Lodotra® start dose 10 mg daily . ( Written inform consent obtain , subject undergo complete evaluation study eligibility ) No dose increase allow 10mg</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients diagnose 3 month Morning stiffness previous treatment without oral steroid ( equal 10mg per day , methylprednisolone dos convert prednisone dos follow : prednisone dosed=methylprednisolone dose*1.25 ) , average daily duration 45 min . Average daily maximum pain intensity score ( 100 mm VAS ) 30mm . DASESR ≥3.2 On DMARD treatment include MTX ≥3months stable treatment dose within past 30 day . There limitation number DMARDs treatment . ( Except patient experience adverse drug reaction MTX difficulty administer MTX due disease specific condition . ) Able perform study procedure give write informed consent . Naïve patient Prednisone MR ( Lodotra® ) patient treat Prednisone MR ( Lodotra® ) within 4 week ( 28days ) Subject keep administer study drug 22±30 daily Subject provide sign dated write voluntary informed consent Patients suffer another disease , require glucocorticoid treatment study period . Synovectomy within 4 month prior study start . Patients underwent joint injection finger wrist ( side ) within 4 week prior first visit . Clinically significant disease , investigator 's opinion , would exclude subject study . Significant renal impairment ( serum creatinine &gt; 2.0mg/dl ) Significant hepatic impairment ( &gt; 3 time upper limit normal range site ) All contraindication glucocorticoid . ( establish new osteoporotic fracture history corticoid psychosis , herpes simplex herpes zoster , varicella infection ) Uncontrolled DM ( HbA1c &gt; 8.0 ) Women childbearing potential , defined woman physiologically capable become pregnant . UNLESS : woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean two birth control method . The two method double barrier method barrier method plus hormonal method . Adequate barrier method contraception include : diaphragm , condom ( partner ) , intrauterine device ( copper hormonal ) , sponge spermicide . Hormonal contraceptive include market contraceptive agent include estrogen and/or progestational agent . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive urine pregnancy test Participation another clinical study within past 30 day Known hypersensitivity prednisone Infection patient without effective antimicrobial systemic mycosis infection patient ( infection might aggravate due suppression immunologic function . ) Patients immunization live vaccine within 2 week enrollment plan study Since drug contains glucose , patient rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption take drug .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>RA , MS , Safety , Efficacy , MR prednisone</keyword>
</DOC>